Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.…
Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
Bluejay Diagnostics (NASDAQ: BJDX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 1.700 USD on 20 November 2026, down 93.2% over 52 weeks. Its 52-week range is 1.620 USD to 28.00 USD: the price is 93.9% below the high and 4.9% above the low.
Its market capitalisation is 1.90M USD.
Bluejay Diagnostics reports return on equity of -114.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 9.52M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.